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OBJECTIVES: The biological functions of transforming growth factor-b signaling that involves Smad proteins have
not been previously investigated with respect to coronary artery bypass grafts. The aim of the present study was to
observe the immunostaining of proteins that are related to this signaling pathway.
METHODS: Fifteen remnants of coronary artery bypass grafts, including nine saphenous veins, three radial arteries
and three mammary arteries, were collected from 12 patients who were undergoing coronary artery bypass.
Hematoxylin and eosin, Masson’s trichrome, and immunohistochemical staining of transforming growth factor-b1,
type I receptor of transforming growth factor-b, Smad2/3, Smad4, and Smad7 were performed.
RESULTS: The saphenous veins showed more severe intimal degeneration, more severe smooth muscle cell
proliferation and more collagen deposition than the arterial grafts, as evidenced by hematoxylin and eosin and
Masson’s trichrome stainings. Immunohistochemical assays demonstrated that the majority of the transforming
growth factor -b1 signaling cytokines were primarily localized in the cytoplasm in the medial layers of all three types
of grafts, whereas ectopic transforming growth factor-b1, type I receptor of transforming growth factor-b, and
Smad7 overexpressions in the interstices were observed particularly in the saphenous vein and radial arterial grafts.
CONCLUSION: Enhanced transforming growth factor-b1 signal transduction with medial smooth muscle cell
proliferation and ectopic transforming growth factor-b1, the presence of the type I receptor of transforming growth
factor-b, and Smad7 overexpressions in the extracellular matrix may provide primary evidence for early or late graft
failure.
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INTRODUCTION
Transforming growth factor (TGF)-b1 is implicated in the
development of intimal hyperplesia subsequent to extracellular
matrix accumulation,1 which increases the thickness of both
arteries and veins.2 The overexpresssion of TGF-b1 is typically
present in the diseased grafts,3 including the saphenous vein and
internal mammary arterial grafts, suggesting that TGF-b1 may
play a role in the irreversible deposition of extracellular matrix
and the further development of intimal hyperplesia.2 Moreover,
TGF-b1 overexpression has also been observed in the intimal
hyperplasia of stenosed venous fistulas for hemodialysis.4
Graft failure is a common issue following coronary
artery bypass grafting5,6 that puzzles cardiac surgeons and
requires increasingly effective solutions. Even though
TGF-b expression has drawn attention to the development
of vascular remodeling, the biological functions of the TGF-
b signaling pathway, including the Smad proteins, have not
been sufficiently investigated with respect to coronary
artery bypass grafts. We have hypothesized that the TGF-b
signaling pathway may be enhanced so as to drive the
fibrotic process that is responsible for the failure of coronary
artery bypass grafts. The aim of the present study was to
observe the immunostaining of the proteins that are related
to this signaling pathway.
MATERIALS AND METHODS
From October 2009 to January 2010, 15 remnants of
coronary artery bypass grafts, including nine saphenous
veins, three radial arteries and three mammary arteries,
were collected from 12 patients who were undergoing
coronary artery bypass after their surgeries. Ten males and
two females were included in the study, and their ages
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ranged from 50 to 83 with a mean of 66.25 ¡ 10.37 years.
The major symptoms were chest/precordial pain in six
patients (50%), chest pain and palpitations in two patients
(16.67%), chest distress in one patient (8.33%), chest distress
and dyspnea in one patient (8.33%), and chest distress and
palpitations in two patients (16.67%). The time since the
onset of symptoms ranged from 1 day to 20 years (mean 5.41
¡ 6.59 years, median 2 years). Hypertension was present in
eight patients (66.67%), and type II diabetes was present in
three patients (25%). Four patients had a myocardial
infarction, two of which were non-ST-segment elevation
myocardial infarctions (NSTEMI), and one patient had a left
ventricular pseudoaneurysmal formation. Conventional cor-
onary artery bypass was performed in four patients (33.33%),
off-pump coronary artery bypass in six patients (50%),
beating heart coronary revascularization in one patient
(8.33%), and off-pump coronary artery bypass with subse-
quent coronary artery bypass in one patient (8.33%). A total
of 41 grafts were bypassed with a mean of 3.42¡ 0.51 grafts
per patient. Thirteen (31.71%) left internal mammary arteries
were grafted, as were one (2.44%) right internal mammary
artery, two (4.88%) radial arteries, and 25 (60.98%) saphenous
veins. The associated procedures included left ventricular
pseudoaneurysmectomy, mitral valve replacement, and
intra-aortic balloon pump insertion in one patient each.
Fresh specimens of the graft remnants were collected and
cut into 1-cm3 blocks/rings and immersed in a 10%
methanol solution in appropriately sized bottles for patho-
logical inspection.
Hematoxylin and eosin (H&E) staining was performed
on the 4-mm sections, and collagen fibers were stained
using Masson’s trichrome protocol. Immunohistochemical
staining was performed on the 4-mm paraffin-embedded
sections to detect TGF-b1, transforming growth factor-b
receptor I (TbRI), Smad2/3, Smad4, and Smad7 using the
Envision method. The following primary antibodies were
utilized: TGF-b1 (Y369) (15150) (Bioworld Technology, Inc.,
Louis Park, MN, USA), TbRI (E161) (15100) (Bioworld
Technology, Inc., Louis Park, MN, USA), Smad2/3 (S2)
(15100) (Beijing Biosynthesis Biotechnology Co., Ltd., Beijing,
China), Smad4 (L43) (15200) (Bioworld Technology, Inc.,
Louis Park, MN, USA), and Smad7 (Z8-B): sc-101152 (15100)
(Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA).
The immunostaining density was characterized as fol-
lows: - (background) was defined as 0, + (weak yellow) as 1,
++ (yellow) as 2, and +++ (brown) as 3 in the semi-
quantitative analyses. Photographs were acquired at6100–
400.
This study was approved by the institutional ethical
committee and was conducted following the guidelines of
the Declaration of Helsinki. Informed consent for the graft
vessel remnants that were used for other than therapeutic
purposes was obtained from each patient in compliance
with the guidelines in ‘‘Surgically Removed Human Tissue
For Research’’ that were proposed by Thasler et al.7
RESULTS
According to H&E staining, the saphenous veins
exhibited proliferative medial smooth muscle cells with
focal or diffuse disruption and severe intimal degenera-
tion (Fig. 1A). The radial arteries exhibited smooth muscle
Figure 1 - Hematoxylin and eosin staining showing (A) proliferative medial smooth muscle cells with inflammatory cell infiltration in
the saphenous veins, (B) focal intimal degeneration with slight disrupted media in the radial arteries, and (C) roughly normal vascular
wall structures of the internal mammary arteries; H&E6200. Masson’s trichrome staining showing that (D) the saphenous veins showed
more collagen deposition but less muscular fibers, (E) the radial arteries showed less collagen deposition and more muscular tissues,
and (F) the mammary arteries showed the least collagen accumulation in the vascular wall but the most muscular tissue; Masson6100.
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cell proliferation, elastic fibrous degeneration and col-
lagenization (Fig. 1B). Evenly distributed smooth muscle
cells of the media with mild degenerative changes in the
intima could be observed in the internal mammary
arteries (Fig. 1C).
Based on Masson’s trichrome staining, the saphenous
veins showed more collagen deposition but less muscular
fibers (Fig. 1D), the radial arteries had less collagen
deposition with more muscular tissues (Fig. 1E), and the
mammary arteries had the least collagen accumulation
in the vascular wall but the most muscular tissues
(Fig. 1F).
Immunostaining demonstrated that the five tested pro-
teins were positive in the cytoplasm of the medial layers of
all three types of grafts. The investigated signaling cytokines
were the most intense in the saphenous vein, followed by
the radial arterial grafts and then the internal mammary
arterial grafts.
Figure 2 - Immunostaining showed that the five tested proteins (TGF-b1, TbRI, Smad2/3, Smad4, and Smad7) were positive, primarily in the
cytoplasm of the medial layers, in all three kinds of grafts. (A) (B) In the saphenous vein and radial arterial grafts, TGF-b1 expression was
moderately positive (++) in the cytoplasm and interstices of the intima, intensely positive (+++) in the cytoplasm and interstices of the
media, and weakly positive (+) in the cytoplasm and interstices of the adventitia. (C) In the intima (++), media (+++) and adventitia (+) of
the internal mammary arterial grafts, TGF-b1 staining was only observed in the cytoplasm and not in the interstices. In the saphenous vein
grafts, TbRI was moderately positive in the cytoplasm and interstices (+-++) of the intima, intensely positive (+++) primarily in the
cytoplasm but also in the nuclei and interstices of the media, and weakly positive (+) or negative (-) in the cytoplasm or interstices,
respectively, of the adventitia (D). This receptor was positive in the cytoplasm and interstices of the intima (+), media (++) and adventitia
(+) of the radial arterial grafts (E), and positive in the cytoplasm of the intima (+), media (++) and adventitia (+) of the internal mammary
arterial grafts (F). Smad2/3 positivity was more intense in the saphenous vein grafts (G) than in the internal mammary arterial grafts (I),
whereas the radial artery (H) showed the least intense Smad2/3 staining. In the saphenous vein grafts, Smad4 was weakly positive (+) in
the cytoplasm of the intima, intensely positive (+++) in the cytoplasm of the media, and weakly positive (--+) in the cytoplasm of the
adventitia (J). In the radial arteries, it was weakly positive in the cytoplasm (+) and negative (-) in the intima, moderately positive (++) in
the cytoplasm and interstices of the media, and weakly positive in the cytoplasm and interstices of the adventitia (K). In the internal
mammary arteries, it was positive in the cytoplasmof the intima (+), media (++), and adventitia (+) (L). Smad7was expressedmost intensely
in the saphenous veins (M), more intense in the radial arteries (N), and it was weaker in scattered nuclei and interstices in the internal
mammary arterial grafts (O). IMA = internal mammary artery; RA = radial artery; SVG = saphenous vein graft; TGF-b1: transforming
growth factor-b1; TbRI: transforming growth factor-b receptor-b receptor I. Envision6200.
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TGF-b1 expression was moderately positive (++) in the
cytoplasm and interstices of the intima, intensely positive
(+++) in the cytoplasm and interstices of the media, and
weakly positive (+) in the cytoplasm and interstices of the
adventitia of the saphenous vein and radial arterial grafts. In
the intima (++), media (+++), and adventitia (+) of the
internal mammary arterial grafts, TGF-b1 staining was seen
only in the cytoplasm and not in the interstices. TGF-b1
staining was the most intense in the internal mammary
artery, less intense in the saphenous vein, and the least
intense in the radial arterial grafts (Fig. 2A–2C).
TbRI was moderately positive in the cytoplasm and
interstices (+-++) of the intima of the saphenous vein grafts,
intensely positive (+++) primarily in the cytoplasm but also
in the nuclei and interstices of the media, and weakly
positive (+) or negative (-) in the cytoplasm and interstices of
the adventitia. This receptor was positive in the cytoplasm
and interstices of the intima (+), media (++) and adventitia
(+) of the radial arterial grafts. It was also positive in the
cytoplasm of the intima (+), media (++) and adventitia (+) of
the internal mammary arterial grafts (Fig. 2D–2F).
Smad2/3 was virtually only present in the cytoplasm.
Smad2/3 positivity was more intense in the saphenous vein
grafts than in the internal mammary arterial grafts, whereas
the radial arteries showed the least intense Smad2/3
staining (Fig. 2G–2I).
In the saphenous vein grafts, Smad4 was weakly positive
(+) in the cytoplasm of the intima, intensely positive (+++) in
the cytoplasm of the media, and weakly positive (--+) in the
cytoplasm of the adventitia, and the positivity rate was
85.71% (6/7). For the radial arteries, Smad4 was weakly
positive in the cytoplasm (+) and negative (-) in the intima,
moderately positive (++) in the cytoplasm and interstices of
the media, and weakly positive in the cytoplasm and
interstices of the adventitia. In the internal mammary
arteries, it was positive in the cytoplasm of the intima (+),
media (++), and adventitia (+) (Fig. 2J–2L).
Smad7 was expressed in the cytoplasm and nucleus and
was also present in the interstices in one of the radial
arteries. Smad7 was the most intense in the saphenous vein,
more intense in the radial artery, and weaker in scattered
nuclei and interstices of the internal mammary arterial
grafts. The positive rates were 62.5% (5/8), 75% (6/8) and
62.5% (5/8), respectively for the intima, media, and
adventitia of the saphenous vein grafts. In the radial artery,
it was negative in 1/3, 1/3 and 2/2 of the intima, media,
and adventitia, respectively (Fig. 2M–2O) (Table 1).
DISCUSSION
Masson’s trichrome staining is a popular technique for
observing collagen deposition between elastin layers, in
which the reactivity and integrity of the vascular wall,8
vascular regeneration, and graft patency9 can all be
assessed. This technique stains the extracellular matrix
blue and the cellular portion red.10 Using Masson’s
trichrome staining, the saphenous veins that were endos-
copically harvested with a no-touch technique showed
well-preserved collagen fibers, whereas those harvested
using conventional techniques showed more subendothe-
lial collagen degradation.11 In comparison, the architec-
tures of the radial arterial grafts were preserved with both
endoscopic and conventional techniques,8 indicating that
the wall structures of the vein grafts were more prone to
being damaged by surgical maneuvers. In addition, the
observed higher durability of the left internal mammary
arterial grafts may be due to their appropriate elastic
tension and internal diameter12, as well as to the relatively
limited atherosclerotic changes.13
TGF-b1 stimulates arteriogenesis, thereby contributing to
the occurrence of restenosis after neointimal damage caused
by angioplasty or stenting. TGF-b1 is upregulated rapidly in
the restenotic and injured vessels following balloon catheter
injury along with associated increases in TGF-b3, activin
receptor-like kinase 5 (ALK-5), and transforming growth
factor-b receptor II (TbRII) immunoreactive peptide levels.14
Smooth muscle cells and macrophages in the atherosclerotic
lesions may be predisposed to the upregulation of TbRII and
ALK5.15 TGF-b antagonists may inhibit fibroblast differentia-
tion and intimal injury following angioplasty,16 and it may
prevent adventitial fibrosis.17 Both TGF-b1 and TGF-b2
upregulate type VII collagen gene expression.18 They may
increase the expression of protease inhibitors, including
inhibitors of matrix metalloproteinases and of tissue plasmi-
nogen activator-1, and theymay crosstalkwith proteins of the
Smad signaling pathway.19 Plasminogen activator inhibitor-1
(PAI-1),20 matrixmetalloproteinases,21 and vascular endothe-
lial growth factor22 have been shown to be modulated by
TGF-b1 and are thus involved in the signal transduction.
In TGF-b signal transduction, Smad2/3 are considered to
be the major mediators of TGF-b-induced fibrotic pathogen-
esis.23 Smad4 is implicated in the pathology of human
vascular disorders, with essential roles in vascular remodel-
ing, maturation, and integrity. Smad4 deficiency may cause
failures of remodeling and efficient sprouting in vivo.24
Smad7 is an inhibitor of TGF-b signaling, and it is usually
expressed in human vascular endothelial cells that have
been injured by shear stress.25 The ectopic expression of
Smad7 inhibits TGF-b responses in vascular smooth muscle
cells, and the biological function of Smad7 can be reversed
by Smad2.26 Conversely, Smad7 overexpression reduces
Smad2 phosphorylation in response to TGF-b1 via TbRI.
27
Smad7 may induce the ubiquitination, degradation, and
endocytosis of TbRI and, hence, play an important role in
the crosstalk between different signaling pathways.
Moreover, an alternative biological function of Smad7 is to
mediate TGF-b-induced apoptosis.28 In addition, it has been
reported that a marked Smad7 deficiency may be respon-
sible for TGF-b hyperresponsiveness.29 The overexpression
of Smad7 had been shown to counteract TGF-b, activin A,
and bone morphogenetic protein-induced growth arrest and
apoptosis in tumor B cell lines,30 and the overexpression of
Smad7 in the adventitia of the carotid arteries significantly
attenuated a-smooth muscle actin expression in the adven-
titia, media, and neointima, or, in other words, in areas of
reduced lumen, after balloon injury.31
Increased flow and shear stress can mediate the release of
TGF-b1 in rabbit arteries.
32 Stress in the endothelial and
smooth muscle cells may alter the synthesis and secretion of
collagen, elastin, and connective tissue proteases.33 Flow
supply to the conduits could be a determinant of graft
patency as evidenced by a series of observations; ,50% or
,70% coronary stenosis may be associated with increased
internal mammary or radial arterial graft occlusion, respec-
tively, during follow-up.34,35 TGF-b1 may promote monocyte
adhesion to the endothelial cells and migration across the
endothelium, probably due to interaction with CD44, which
may link more to TbRI than to TbRII, thereby increasing
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Smad2/3 phosphorylation.36 TGF gene expressionwas found
to be increased in arterialized vein grafts from the coronary
artery bypasses.37,38 Therefore, the ectopic implantation of
either venous or arterial grafts into the coronary circulation
may place these vessels in a state of increased stress, which
may upregulate TGF-b signaling cytokines.
We found that the internal mammary arteries showed a
weak Smad7 expression. Therefore, the dual regulatory
effects of TGF-b on the activation and phosphorylation of
the Smad proteins may lead to the normal transcription of
target genes. The most prominent difference in the signaling
pathways between the three grafts may lie in the ectopic
TGF-b1, TbRI, and Smad7 overexpression in the interstices
was observed particularly in the saphenous veins and radial
arteries relative to the internal mammary arteries. Therefore,
the increased TGF-b signaling activity in the extracellular
matrix of the saphenous vein and radial arterial grafts may
lead to considerable proliferation of the intima and
muscular layers of these the grafts.
CONCLUSION
In conclusion, severe vascular wall degeneration and
collagen deposition together with overexpressed TGF-b
signaling cytokines may provide preliminary evidence for
the failure (early or late) of the saphenous vein and radial
arterial grafts. Weak Smad7 expression in the internal
mammary arterial grafts with well-preserved structures
may imply less matrix deposition, which may explain their
superior durability. More comprehensive studies of the
grafts are required to obtain more accurate information for
the prevention of graft disorders.
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